Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2022; 10(18): 6009-6020
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6009
Prostate sclerosing adenopathy: A clinicopathological and immunohistochemical study of twelve patients
Run-Lin Feng, Yan-Ping Tao, Zhi-Yong Tan, Shi Fu, Hai-Feng Wang
Run-Lin Feng, Department of Pathology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China
Yan-Ping Tao, Department of Emergency, Kunming Third People's Hospital, Kunming 650000, Yunnan Province, China
Zhi-Yong Tan, Shi Fu, Hai-Feng Wang, Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China
Author contributions: Feng RL and Tan ZY contributed equally to this work; Feng RL, Tao YP, Fu S, and Wang HF designed the study; Tan ZY and Tao YP contributed new reagents and analytical tools; Tao YP, Fu S and Wang HF analyzed data; Feng RL and Tan ZY wrote the manuscript. All authors have read and approved the final manuscript.
Institutional review board statement: The study was authorized by the Ethics Committee at The Second Affiliated Hospital of Kunming Medical University.
Conflict-of-interest statement: The authors declared that no competing interests exist.
Data sharing statement: On reasonable request, the corresponding author will provide the analyzed datasets generated during the study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed by the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Feng Wang, PhD, Chief Doctor, Department of Urology, The Second Affiliated Hospital of Kunming Medical University, No. 374 Yunnan-Burma Avenue, Kunming 650101, Yunnan Province, China. wanghaifeng@kmmu.edu.cn
Received: November 2, 2021
Peer-review started: November 2, 2021
First decision: April 7, 2022
Revised: April 19, 2022
Accepted: April 30, 2022
Article in press: April 30, 2022
Published online: June 26, 2022
Core Tip

Core Tip: Sclerosing prostatic adenopathy is a rare pseudoadenocarcinoma proliferative lesion with a unique histomorphology and immunohistochemical phenotype. Compared to the common prostate adenocarcinoma, the incidence of sclerosing prostatic adenopathy is low, and we are under-recognized and have a high rate of misdiagnosis. Meanwhile, there are no large samples of data available to clinicopathologic to date because it is a rare lesion. To further our understanding of prostatic sclerosing adenopathy, this study aimed to investigate the histopathological morphology and immunohistochemical phenotype of this very rare prostate lesion and to further explore its associated biological significance.